RT Journal Article
SR Electronic
T1 COVID-19 prognostic model using Bayesian networks learnt on patient data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.24.22281436
DO 10.1101/2022.10.24.22281436
A1 Bernaola, Nikolas
A1 Bielza, Concha
A1 Larrañaga, Pedro
YR 2022
UL http://medrxiv.org/content/early/2022/10/26/2022.10.24.22281436.abstract
AB The response to the ongoing second wave of the COVID-19 pandemic can be helped by giving medical professionals access to models learned on patient data. To achieve this, we learned a Bayesian network model to predict risk of ICU admission, death and time of stay in the hospital from patient history, initial vital signs, initial laboratory tests and medication. Data were obtained from patients that were admitted to an HM hospital with suspicion of COVID-19 until 24/04/2020, excluding unconfirmed diagnosis, those who were admitted before the epidemic started in Madrid, had an outcome that was not discharge or death or died within 24 hours of presentation. Relevant variables for the model were selected with help from medical professionals. We learned the model using Bayesian search as implemented in GeNIe. Of 2,307 patients in the dataset, 679 were excluded. With the remaining 1,645 patients, we learned a model that predicted death with 86.4% accuracy. Some of the initial variables were discarded because they were independent of the outcomes of interest conditioned on some of the other variables. This high redundancy might be useful to build simpler tests for the severity of COVID-19. We show how the model can be used at different stages of patient admission and even with only partial information about the patient. This can be done by clinicians that want a fast second opinion or a summary of the available data from previous patients similar to the one at hand. We then include how we plan to improve the model with extra patient data and how it could be expanded to other contexts, like for example, an epidemiological one.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the BBVA COVID AI GrantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics comittee of HM Hospitals gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are avaiable upon request to the HM hospitals through the Covid Data saves lives initiative https://www.hmhospitales.com/coronavirus/covid-data-save-lives/english-version